MXPA01011344A
(es)
*
|
1999-05-07 |
2004-06-03 |
Univ Johns Hopkins Med |
El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
WO2001057020A1
(fr)
*
|
2000-02-01 |
2001-08-09 |
Cor Therapeutics, Inc. |
Indole et benzimidazole utilises comme inhibiteurs du facteur xa
|
JP2001302667A
(ja)
*
|
2000-04-28 |
2001-10-31 |
Bayer Ag |
イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
|
ES2556946T3
(es)
|
2000-12-21 |
2016-01-21 |
Novartis Ag |
Pirimidinaminas como moduladores de la angiogénesis
|
MX349009B
(es)
|
2001-01-05 |
2017-07-06 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
|
RU2259825C9
(ru)
|
2001-06-18 |
2006-04-10 |
БиоДием Лимитед |
Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
EP1460067A4
(fr)
*
|
2001-11-26 |
2005-12-07 |
Takeda Pharmaceutical |
Derive bicyclique, procede de production de ce derive et utilisation correspondante
|
BR0308162A
(pt)
|
2002-03-01 |
2004-12-07 |
Pfizer |
Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
|
EP1482931B1
(fr)
|
2002-03-05 |
2011-10-19 |
TransTech Pharma, Inc. |
Derives de l'azole et derives bicycliques fusionnes de l'azole, agents therapeutiques
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
PA8580301A1
(es)
|
2002-08-28 |
2005-05-24 |
Pfizer Prod Inc |
Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
|
BR0316229A
(pt)
|
2002-11-13 |
2005-10-04 |
Chiron Corp |
Métodos de tratamento de câncer e métodos relacionados
|
BR0317548A
(pt)
|
2002-12-19 |
2005-11-22 |
Pfizer |
Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
|
DK2476667T3
(da)
|
2003-02-26 |
2014-09-15 |
Sugen Inc |
Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
|
ES2314444T3
(es)
|
2003-08-29 |
2009-03-16 |
Pfizer Inc. |
Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
CA2551508C
(fr)
|
2003-12-23 |
2011-08-09 |
Pfizer Inc. |
Derives nouveaux de quinoleine
|
EP1711496A4
(fr)
|
2004-01-28 |
2009-02-11 |
Smithkline Beecham Corp |
Composes thiazole
|
CN1960731B
(zh)
|
2004-02-20 |
2011-12-07 |
诺华疫苗和诊断公司 |
调节炎性和转移过程的方法
|
BRPI0511722A
(pt)
|
2004-06-01 |
2008-01-08 |
Hoffmann La Roche |
3-amino-1-arilpropilindóis como inibidores da recaptação de monoamina
|
MXPA06014797A
(es)
|
2004-06-17 |
2007-02-16 |
Wyeth Corp |
Procesos para preparacion de antagonistas de receptor de hormona que libera gonadotropina.
|
US7696210B2
(en)
|
2004-06-17 |
2010-04-13 |
Wyeth |
Gonadotropin releasing hormone receptor antagonists
|
UA87153C2
(ru)
|
2004-08-26 |
2009-06-25 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
DOP2006000051A
(es)
|
2005-02-24 |
2006-08-31 |
Lilly Co Eli |
Inhibidores de vegf-r2 y métodos
|
EP2444099A1
(fr)
|
2005-03-31 |
2012-04-25 |
Agensys, Inc. |
Anticorps et molécules correspondantes se liant aux protéines 161P2F10B
|
EP2444419A1
(fr)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
Anticorps de la P-Cadherine
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
MX2007014782A
(es)
|
2005-05-23 |
2008-02-19 |
Novartis Ag |
Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
UA94060C2
(ru)
|
2005-09-07 |
2011-04-11 |
Эмджен Фримонт Инк. |
Моноклональное антитело, которое специфически связывает alk-1
|
CA2623125A1
(fr)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Marqueurs biologiques predictifs d'une reaction anticancereuse aux inhibiteurs kinase du recepteur du facteur de croissance 1 analogue a l'insuline
|
KR20080072753A
(ko)
|
2005-11-30 |
2008-08-06 |
에프. 호프만-라 로슈 아게 |
3-아미노-1-아릴프로필 인돌 및 아자-치환된 인돌
|
EP1957488B1
(fr)
|
2005-11-30 |
2009-09-09 |
F.Hoffmann-La Roche Ag |
3-amino-2-arylpropyl azaindoles et leurs utilisations
|
BRPI0619247A2
(pt)
|
2005-11-30 |
2011-09-20 |
Hoffmann La Roche |
métodos para a sìntese de 3-amino-1-aril-propila indóis
|
TWI417095B
(zh)
|
2006-03-15 |
2013-12-01 |
Janssen Pharmaceuticals Inc |
1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
|
CN101490046A
(zh)
|
2006-05-09 |
2009-07-22 |
辉瑞产品公司 |
环烷基氨基酸衍生物及其药物组合物
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
DK2185574T3
(da)
|
2007-09-07 |
2013-08-05 |
Agensys Inc |
Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner
|
RS51660B
(en)
|
2007-09-14 |
2011-10-31 |
Ortho-Mcneil-Janssen Pharmaceuticals Inc. |
1`, 3`-DISUPSTITUATED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1`H- [1,4`] BIPYRIDINYL-2`-ONE
|
RU2510396C2
(ru)
|
2008-09-02 |
2014-03-27 |
Янссен Фармасьютикалз, Инк. |
3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
|
US8507473B2
(en)
|
2008-09-11 |
2013-08-13 |
Arena Pharmaceuticals, Inc. |
3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
|
CA2737597C
(fr)
|
2008-10-16 |
2017-03-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Anticorps entierement humains diriges contre un antigene associe au melanome de masse moleculaire elevee et leurs utilisations
|
RU2512283C2
(ru)
|
2008-11-28 |
2014-04-10 |
Янссен Фармасьютикалз, Инк. |
Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов
|
US20100204221A1
(en)
|
2009-02-09 |
2010-08-12 |
Hariprasad Vankayalapati |
Pyrrolopyrimidinyl axl kinase inhibitors
|
JP2012518657A
(ja)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
併用抗癌治療
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010099363A1
(fr)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
|
WO2010098866A1
(fr)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase
|
WO2010099138A2
(fr)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
|
MY153912A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
ME01573B
(me)
|
2009-05-12 |
2014-09-20 |
Addex Pharma Sa |
DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
KR20120106935A
(ko)
|
2009-07-13 |
2012-09-27 |
제넨테크, 인크. |
암의 치료를 위한 진단 방법 및 조성물
|
WO2011014726A1
(fr)
|
2009-07-31 |
2011-02-03 |
Osi Pharmaceuticals, Inc. |
Polythérapie par inhibiteur de mtor et inhibiteur de langiogenèse
|
WO2011027249A2
(fr)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Dérivés de benzimidazole
|
WO2011032013A1
(fr)
|
2009-09-11 |
2011-03-17 |
Genentech, Inc. |
Procédé pour identifier un patient plus fortement susceptible de répondre à un anticancéreux
|
CN102612566B
(zh)
|
2009-09-17 |
2016-02-17 |
霍夫曼-拉罗奇有限公司 |
用于癌症患者中诊断学用途的方法和组合物
|
WO2011041198A1
(fr)
|
2009-09-30 |
2011-04-07 |
Transtech Pharma, Inc. |
Dérivés d'imidazole substitués pour traiter la maladie d'alzheimer
|
WO2011073521A1
(fr)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations
|
RU2570198C2
(ru)
|
2010-02-12 |
2015-12-10 |
Пфайзер Инк. |
СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА
|
AU2011223655A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011153224A2
(fr)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Procédés diagnostiques et compositions de traitement du cancer
|
ES2695899T3
(es)
|
2010-06-16 |
2019-01-11 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Anticuerpos contra endoplasmina y su uso
|
EP2866032A1
(fr)
|
2010-07-19 |
2015-04-29 |
F. Hoffmann-La Roche AG |
Procédé pour identifier un patient avec une forte probabilité de réaction à une thérapie anticancéreuse
|
CA2804246A1
(fr)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Methode d'identification d'un patient presentant une probabilite accrue de repondre a un traitement anticancereux
|
EP2596026B1
(fr)
|
2010-07-23 |
2020-04-08 |
Trustees of Boston University |
Inhibiteurs anti-despr comme agents thérapeutiques pour l'inhibition de l'angiogenèse pathologique et de l'invasivité des cellules tumorales et pour l'imagerie moléculaire et l'administration ciblée
|
WO2012042421A1
(fr)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Procédé de traitement de la croissance cellulaire anormale
|
CA2813162C
(fr)
|
2010-10-20 |
2015-06-16 |
Pfizer Inc. |
Derives de pyridine-2 en tant que modulateurs des recepteurs smoothened
|
CA2814996C
(fr)
|
2010-11-08 |
2019-10-01 |
Janssen Pharmaceuticals, Inc. |
Derives de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
|
CN103261195B
(zh)
|
2010-11-08 |
2015-09-02 |
杨森制药公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
|
WO2012062759A1
(fr)
|
2010-11-08 |
2012-05-18 |
Janssen Pharmaceuticals, Inc. |
Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
WO2012142164A1
(fr)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Anticorps monoclonaux humains qui se lient aux facteurs de croissance insulinomimétique (igf) de type i et ii
|
US20140178368A1
(en)
|
2011-04-19 |
2014-06-26 |
Leslie Lynne SHARP |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
UA110259C2
(uk)
|
2011-09-22 |
2015-12-10 |
Пфайзер Інк. |
Похідні піролопіримідину і пурину
|
US9783613B2
(en)
|
2011-10-04 |
2017-10-10 |
Igem Therapeutics Limited |
IgE anti-HMW-MAA antibody
|
RU2014114015A
(ru)
|
2011-11-08 |
2015-12-20 |
Пфайзер Инк. |
Способы лечения воспалительных расстройств с использованием антител против m-csf
|
KR20130076046A
(ko)
*
|
2011-12-28 |
2013-07-08 |
한미약품 주식회사 |
타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
|
WO2013152252A1
(fr)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Polythérapie antinéoplasique
|
TWI569799B
(zh)
|
2012-09-21 |
2017-02-11 |
安羅格製藥股份有限公司 |
抑制組成型活性磷酸化flt3激酶的方法
|
US11642340B2
(en)
|
2012-09-26 |
2023-05-09 |
Arog Pharmaceuticals, Inc. |
Method of inhibiting mutant C-KIT
|
US10835525B2
(en)
|
2012-09-26 |
2020-11-17 |
Arog Pharmaceuticals, Inc. |
Method of inhibiting mutant C-KIT
|
TWI599356B
(zh)
|
2012-09-26 |
2017-09-21 |
安羅格製藥有限責任公司 |
抑制突變型c-kit的方法
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
GB201223265D0
(en)
*
|
2012-12-21 |
2013-02-06 |
Selvita Sa |
Novel benzimidazole derivatives as kinase inhibitors
|
BR112015016282A2
(pt)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
|
MX2015012062A
(es)
|
2013-03-14 |
2016-05-05 |
Tolero Pharmaceuticals Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
KR102502485B1
(ko)
|
2014-01-21 |
2023-02-21 |
얀센 파마슈티카 엔.브이. |
대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
|
UA121965C2
(uk)
|
2014-01-21 |
2020-08-25 |
Янссен Фармацевтика Нв |
Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
|
EP3126528B1
(fr)
|
2014-04-04 |
2021-08-18 |
Crown Bioscience, Inc. (Taicang) |
Méthodes permettant de déterminer la sensibilité à des inhibiteurs de mek/erk
|
WO2015155624A1
(fr)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dérivés de dihydropyrrolopyrimidine
|
CR20160497A
(es)
|
2014-04-30 |
2016-12-20 |
Pfizer |
Derivados de diheterociclo enlazado a cicloalquilo
|
WO2016001789A1
(fr)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
|
ES2925224T3
(es)
|
2014-07-31 |
2022-10-14 |
Us Gov Health & Human Services |
Anticuerpos monoclonales humanos contra EphA4 y su uso
|
EP3233829B1
(fr)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
|
AU2016252609B2
(en)
|
2015-04-20 |
2022-06-30 |
Sumitomo Pharma Oncology, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
US10011629B2
(en)
|
2015-05-01 |
2018-07-03 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
TR201911032T4
(tr)
|
2015-05-18 |
2019-08-21 |
Tolero Pharmaceuticals Inc |
Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
|
WO2017009751A1
(fr)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Dérivés de pyrimidine
|
RU2759963C2
(ru)
|
2015-08-03 |
2021-11-19 |
Сумитомо Даиниппон Фарма Онколоджи, Инк. |
Комбинированные терапии для лечения рака
|
AU2016315881B2
(en)
|
2015-09-03 |
2019-09-19 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Small molecule inhibitors of DYRK1A and uses thereof
|
US20180371551A1
(en)
|
2015-12-03 |
2018-12-27 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
EP3359155A4
(fr)
|
2016-11-02 |
2019-05-22 |
Arog Pharmaceuticals, Inc. |
Utilisation de crenolanib pour traiter les mutations associées à des troubles prolifératifs à mutation flt3
|
WO2018094275A1
(fr)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
|
WO2018119000A1
(fr)
|
2016-12-19 |
2018-06-28 |
Tolero Pharmaceuticals, Inc. |
Peptides de profilage et procédés de profilage de sensibilité
|
WO2019055579A1
(fr)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib
|
WO2019075367A1
(fr)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer
|
AU2019310590A1
(en)
|
2018-07-26 |
2021-01-14 |
Sumitomo Pharma Oncology, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
CN113490499A
(zh)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
|
CN110840893A
(zh)
|
2018-12-13 |
2020-02-28 |
安罗格制药有限责任公司 |
含克莱拉尼的药物组合物及其用途
|
KR20210146290A
(ko)
|
2019-02-12 |
2021-12-03 |
스미토모 다이니폰 파마 온콜로지, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
AU2020245437A1
(en)
|
2019-03-22 |
2021-09-30 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
US11465998B2
(en)
|
2019-04-25 |
2022-10-11 |
Regents Of The University Of Minnesota |
Therapeutic compounds and methods of use thereof
|
US11471451B2
(en)
|
2019-08-19 |
2022-10-18 |
Arog Pharmaceuticals, Inc. |
Uses of crenolanib
|
WO2021155006A1
(fr)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
|
US11713310B2
(en)
|
2020-07-20 |
2023-08-01 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
US11524006B2
(en)
|
2020-09-17 |
2022-12-13 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating TRK kinase associated proliferative disorders
|
US11969420B2
(en)
|
2020-10-30 |
2024-04-30 |
Arog Pharmaceuticals, Inc. |
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
|
JP2023063189A
(ja)
|
2021-10-22 |
2023-05-09 |
アログ・ファーマシューティカルズ・インコーポレイテッド |
以前の治療に対して再発性/不応性のflt3突然変異増殖性障害を治療するためのクレノラニブ
|